Get the Stockscreener App
90.46
0.79%
-0.72
After Hours:
89.25
-1.21
-1.34%
Edwards Lifesciences Corp stock is traded at $90.46, with a volume of 3.59M.
It is down -0.79% in the last 24 hours and up +4.61% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$91.18
Open:
$91.53
24h Volume:
3.59M
Relative Volume:
0.69
Market Cap:
$52.09B
Revenue:
$6.30B
Net Income/Loss:
$1.07B
P/E Ratio:
49.15
EPS:
1.8406
Net Cash Flow:
$1.09B
1W Performance:
+4.04%
1M Performance:
+4.61%
6M Performance:
+4.94%
1Y Performance:
+15.66%
1-Day Range:
$89.69
$92.00
1-Week Range:
$87.00
$92.88
52-Week Range:
$72.30
$92.88
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
90.46 | 52.27B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
90.74 | 163.94B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
314.84 | 127.55B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.23 | 103.66B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
42.68 | 65.74B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-01-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-26 | Upgrade | TD Cowen | Hold → Buy |
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-03-25 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-29-25 | Upgrade | Jefferies | Hold → Buy |
| Oct-29-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-29-25 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
BTIG Adjusts Price Target on Edwards Lifesciences to $110 From $100, Maintains Buy Rating - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Edwards Lifesciences (EW) Gains FDA Approval for Ecliptis System - GuruFocus
Edwards Lifesciences Corporation(NYSE: EW) added to Russell Midcap Value Benchmark - marketscreener.com
Edwards Lifesciences: The Heart of OC Medtech - Orange County Business Journal
Edwards Lifesciences presents fresh trial data, shares supported by robust S&P 500 positioning - AD HOC NEWS
Edwards Lifesciences Corporation $EW Shares Sold by OLD National Bancorp IN - MarketBeat
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences Reports New Clinical Trial Updates - Orange County Business Journal
Edwards Lifesciences presents trial data at New York conference - Investing.com
Edwards brings fresh valve data to New York, with TAVR study update - Stock Titan
A Look at Edwards Lifesciences Corp (EW) After 3.1% Gain -- GF V - GuruFocus
Edwards Lifesciences stock hits 52-week high at 89.7 USD By Investing.com - Investing.com South Africa
Edwards Lifesciences stock hits 52-week high at 89.7 USD - Investing.com
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences clears fresh Medicare hurdle, shares consolidate after 52-week high - Ad-hoc-news.de
Edwards Lifesciences Corp (EW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SAPIEN 3 Ultra from Edwards Lifesciences Corp.lower-profile TAVI and refined delivery - AD HOC NEWS
Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors - MarketWatch
Edwards Lifesciences Stocklong-term heart valve strategy in focus - AD HOC NEWS
Why Edwards Lifesciences’ Sapien 3 Ultra Resilia aims for quieter TAVI procedures - AD HOC NEWS
Top Edwards Lifesciences (EW) Competitors 2026 - MarketBeat
Edwards Lifesciences CEO Zovighian sells $45,982 of stock By Investing.com - Investing.com India
Edwards Lifesciences CEO Zovighian sells $45,982 of stock - Investing.com
Edwards Lifesciences Corp (EW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Edwards Lifesciences Corp (EW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Edwards Lifesciences Corp (EW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Edwards Lifesciences (EW) CEO sells 523 shares under Rule 10b5-1 plan - Stock Titan
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Edwards Lifesciences Corp (EW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Edwards Lifesciences (EW) Hits 52-Week High on Medicare Coverage Proposal - GuruFocus
Edwards Lifesciences (EW) Sees Gains Following CMS Coverage Prop - GuruFocus
Edwards Lifesciences (EW) Sees 3% Rise Following CMS Coverage An - GuruFocus
Edwards Lifesciences (EW) Sees Positive Coverage Update Boosting Stock Prospects - GuruFocus
Edwards Lifesciences (EW) Gains Analyst Support Amid Coverage Up - GuruFocus
Edwards Lifesciences (EW) Set to Gain from Medicare Coverage Exp - GuruFocus
Edwards Lifesciences Stands Out As US Agency Eyes Broader Access For Heart Valve Device - Benzinga
Edwards Lifesciences jumps as CMS posts proposed TAVR coverage update - Quiver Quantitative
Is Edwards Lifesciences Ready For Its Next Growth Phase? - Kalkine Media
Edwards Lifesciences stock hits 52-week high at $89.50 By Investing.com - Investing.com Nigeria
Edwards Lifesciences stock hits 52-week high at $89.50 - Investing.com
Why is Edwards Lifesciences stock climbing today? - Investing.com
Edwards Lifesciences stock jumps on TAVR coverage proposal - Investing.com
Leerink reiterates Edwards Lifesciences stock rating on TAVR policy - Investing.com
Leerink reiterates Edwards Lifesciences stock rating on TAVR policy By Investing.com - Investing.com UK
Edwards Lifesciences Corp. stock rises Monday, still underperforms market - MarketWatch
Edwards Lifesciences Stock (US28176E1082): Valuation Metrics Under the Microscope - AD HOC NEWS
Is Edwards Lifesciences stock underperforming the Nasdaq? - MSN
Sector Gamma AS Acquires 23,422 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Parnassus Investments LLC Acquires 111,843 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Stock Watched As Procedure Recovery Matters - Kalkine Media
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):